TY  -  
T1  - Selective JAKinibs : Prospects in Inflammatory and Autoimmune Diseases 
SN  -  /  
UR  - http://hdl.handle.net/10138/305060 
T3  -  
A1  - T. Virtanen, Anniina; Haikarainen, Teemu; Raivola, Juuli; Silvennoinen, Olli 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers and Activators of Transcription) pathway, play a central role in the pathogenesis of inflammatory and autoimmune diseases. Currently three JAK inhibitors have been approved for clinical use in USA and/or Europe: tofacitinib for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, baricitinib for rheumatoid arthritis, and ruxolitinib for myeloproliferative neoplasms. The clinical JAK inhibitors targ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - 1182 Biochemistry, cell and molecular biology; JANUS KINASE INHIBITOR; ACTIVE RHEUMATOID-ARTHRITIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MODIFYING ANTIRHEUMATIC DRUG; NATURAL-KILLER-CELLS; DOUBLE-BLIND; INADEQUATE RESPONSE; VX-509 DECERNOTINIB; ANKYLOSING-SPONDYLITIS; JAK1 INHIBITOR 
N1  -   
PP  -  
ER  -